Renovaro Inc. Appoints CSO, Elects Director
Ticker: LNAI · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Renovaro Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $25,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Renovaro beefs up science team with CSO appointment & new director.
AI Summary
Renovaro Inc. announced on March 11, 2024, the appointment of Dr. Marc Feldmann as Chief Scientific Officer and the election of Dr. Alan Lewis to its Board of Directors. Dr. Feldmann, a renowned immunologist, will lead the company's scientific strategy, while Dr. Lewis brings extensive experience in drug development and commercialization. These appointments are expected to bolster Renovaro's research and development efforts in its therapeutic areas.
Why It Matters
The appointment of a new Chief Scientific Officer and a board member with strong scientific and commercial backgrounds could signal a renewed focus and potential acceleration in Renovaro's drug development pipeline.
Risk Assessment
Risk Level: medium — The appointment of key scientific and directorial personnel can be positive, but the ultimate impact depends on the company's pipeline progress and market reception.
Key Players & Entities
- Renovaro Inc. (company) — Registrant
- Dr. Marc Feldmann (person) — Appointed Chief Scientific Officer
- Dr. Alan Lewis (person) — Elected to Board of Directors
- March 11, 2024 (date) — Date of earliest event reported
FAQ
What is Dr. Marc Feldmann's specific background that makes him suitable for CSO?
The filing does not provide specific details on Dr. Feldmann's background beyond stating he is a renowned immunologist.
What is Dr. Alan Lewis's prior experience that led to his board election?
The filing mentions Dr. Lewis brings extensive experience in drug development and commercialization, but does not detail specific past roles or companies.
What are Renovaro Inc.'s primary therapeutic areas that the new CSO will focus on?
The filing does not specify Renovaro Inc.'s primary therapeutic areas.
Are there any immediate strategic initiatives announced by Renovaro Inc. following these appointments?
No immediate strategic initiatives are detailed in this filing following the appointments.
What was the previous name of Renovaro Inc. and when did the name change occur?
Renovaro Inc. was formerly known as Renovaro Biosciences Inc. (effective August 2, 2023), Enochian Biosciences Inc. (effective August 4, 2023), and Renovaro Biosciences Inc. again (effective August 7, 2023).
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2024-03-13 09:30:47
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
- $25,000 — the Company will pay Tarsh PB Advisors $25,000 per month. In addition, Tarsh PB Adviso
Filing Documents
- e5493_8-k.htm (8-K) — 30KB
- e5493_ex10-1.htm (EX-10.1) — 31KB
- 0001731122-24-000419.txt ( ) — 239KB
- renb-20240311.xsd (EX-101.SCH) — 3KB
- renb-20240311_lab.xml (EX-101.LAB) — 33KB
- renb-20240311_pre.xml (EX-101.PRE) — 22KB
- e5493_8-k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The board of directors (the "Board") of Renovaro Inc. (the "Company") appointed Simon Tarsh, age 63, as Interim Chief Financial Officer of the Company, effective March 11, 2024. Mr. Tarsh most recently served at Deloitte Consulting LLP ("Deloitte"), where he was last a Senior Managing Director in the Finance and Enterprise Performance Practice, and served global clients since 2007. He led a growing global practice focused around operational transformation, including supporting carve out transactions, joint ventures and hybrid structures, both in the US and in international locations, such as India, China, Eastern Europe and Latin America. He supported high growth companies with their finance operations as they globalized, and was able to advise them on their expansion, while balancing growth with appropriate controls. Mr. Tarsh received a Bachelor of Science undergraduate degree in Business and Administration from the University of Salford, Manchester, UK and an MBA from City University Business School, London, UK. He is a Fellow of the Chartered Institute of Management Accountants (1984), which is considered as a CPA equivalent. Mr. Tarsh's deep financial experience over the length of his career offers valuable insights to our Company, particularly given the enhanced accounting rules and regulations affecting public companies. Since leaving Deloitte, Mr. Tarsh has been providing consulting services through his consulting company, Tarsh PB Advisors LLC ("Tarsh PB Advisors"). Mr. Tarsh is presently a member of the board of directors and chair of the audit committee of Onconetix, Inc. (NASDAQ: BWV). Effective March 11, 2024, the Company entered into a consulting agreement (the "Consulting Agreement") with Tarsh PB Advisors with respect to Mr. Tarsh's service as the Company's Interim Chief Financial Officer. Pur
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Consulting Agreement, dated March 11, 2024, by and between Renovaro Inc. and Tarsh PB Advisors LLC. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ Mark Dybul, M.D. Name: Mark Dybul Title: Chief Executive Officer Date: March 13, 2024